The Biological Basis of Histologic Transformation

Area of Science:

• Hematologic Malignancies
• Oncology
• Immunotherapy

Background:

• Histologic transformation of follicular lymphoma (FL) is the primary driver of mortality, even with rituximab therapy.
• The varied timing and genomic heterogeneity of transformation suggest distinct underlying disease processes.
• Current understanding of FL transformation predates modern anti-CD20 therapies, necessitating updated research.

Purpose of the Study:

• To investigate the distinct biological entities of histologic transformation in follicular lymphoma.
• To explore the clonal evolution patterns in indolent and transformed FL.
• To identify potential therapeutic targets and clinical opportunities for managing FL transformation.

Main Methods:

• Analysis of successive indolent and transformed follicular lymphoma episodes.
• Investigation of divergent clonal evolution from a common progenitor cell.
• Review of existing biological knowledge in the context of anti-CD20 therapy.

Main Results:

• Histologic transformation represents a significant cause of mortality in follicular lymphoma patients treated with rituximab.
• Follicular lymphoma transformation may encompass distinct disease entities due to heterogeneous genomic events and diverse transformation timing.
• Clonal evolution occurs divergently from a common progenitor cell in successive indolent and transformed phases, indicating a potential therapeutic target.

Conclusions:

• Histologic transformation of follicular lymphoma necessitates further prospective validation, especially considering anti-CD20 therapies.
• Integrating genetic and microenvironmental factors is crucial for understanding FL transformation.
• Clinical trials incorporating biomarker discovery for transformation cases may reveal new therapeutic avenues.